Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): A 2-year randomized placebo-controlled trial

European Journal of Pediatrics

Volumn 166, Issue 11, 2007, Pages 1155-1161

  Kok, Dieke H J ^a   Sakkers, Ralph J B ^a   Janse, Arieke J ^a   Pruijs, Hans E H ^a   Verbout, Ab J ^a   Castelein, Rene M ^a   Engelbert, Raoul H H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bisphosphonates; Children; Health related quality of life (HRQL); Osteogenesis imperfecta; Randomized

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; OLPADRONIC ACID; PLACEBO;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; ESOPHAGITIS; FEMALE; FOLLOW UP; GENDER; HUMAN; MALE; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SELF CONCEPT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WALKING DIFFICULTY;

ACHIEVEMENT; ADMINISTRATION, ORAL; CHILD; DIPHOSPHONATES; DOUBLE-BLIND METHOD; HUMANS; OSTEOGENESIS IMPERFECTA; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SELF CONCEPT; SEVERITY OF ILLNESS INDEX; SOCIOMETRIC TECHNIQUES;

EID: 34748880591     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-006-0399-2     Document Type: Article

References (41)

1. Astrom E, Soderhall S (1998) Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87:64-68
2. Bleck EE (1981) Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop 111-122
3. Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 38:1-10
4. Boyle MH, Furlong W, Feeny D, Torrance GW, Hatcher J (1995) Reliability of the Health Utilities Index-Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 4:249-257
5. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266-283
6. Byers PH (1989) Inherited disorders of collagen gene structure and expression. Am J Med Genet 34:72-80
7. Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/ pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551-570
8. Dimeglio LA, Ford L, McClintock C, Peacock M (2005) A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 18:43-53
9. Engelbert RH, Gulmans VA, Uiterwaal CS, Helders PJ (2001) Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability. Arch Phys Med Rehabil 82:943-948
10. Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ (2004) Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil 85:772-778
11. Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ (2000) Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr 137:397-402
12. Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs HE, Helders PJ (2000) Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire. Eur J Pediatr 159:615-620
13. Erling A (1999) Methodological considerations in the assessment of health-related quality of life in children. Acta Paediatr Suppl 88:106-107
14. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M (2002) Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 40:113-128
15. Furlong W et al (2005) Multiplicative multi-attribute utility function for the health utilities index mark 3 (HUI3) system: a technical report. CEHPA WP#98-11. Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Canada, pp 76, 96
16. Furlong W, Barr RD, Feeny D, Yandow S (2005) Patient-focused measures of functional health status and health-related quality of life in pediatric orthopedics: a case study in measurement selection. Health Qual Life Outcomes 3:3
17. Furlong WJ, Feeny DH, Torrance GW, Barr RD (2001) The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 33:375-384
18. Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758-763
19. Gemke RJ, Bonsel GJ (1996) Reliability and validity of a comprehensive health status measure in a heterogeneous population of children admitted to intensive care. J Clin Epidemiol 49:327-333
20. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
21. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ (2000) Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 15:1650-1658
22. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17:30-38
23. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14:529-533
24. Harter S (1982) The perceived competence scale for children. Child Develop 53:87-97
25. Horsman J, Furlong W, Feeny D, Torrance G (2003) The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health Qual Life Outcomes 1:54
26. Janse AJ, Uiterwaal CS, Gemke RJ, Kimpen JL, Sinnema G (2005) A difference in perception of quality of life in chronically ill children was found between parents and pediatricians. J Clin Epidemiol 58:495-502
27. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE (1997) Treatment of osteogenesis imperfecta with the bisphosphonate Olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 156:792-794
28. Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R (1993) The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 75:1619-1626
29. Laupacis A, Rorabeck CH, Bourne RB, Feeny D, Tugwell P, Sim DA (1989) Randomized trials in orthopaedics: why, how, and when? J Bone Joint Surg Am 71:535-543
30. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977-986
31. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850
32. Roughley PJ, Rauch F, Glorieux FH (2003) Osteogenesis imperfecta-clinical and molecular diversity. Eur Cell Mater 5:41-47
33. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with Olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427-1431
34. Schipper HS, Clinch JJ, Olwenly CLM (1996) Quality of life studies: definitions and conceptual issues. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 11-23
35. Shevlin M, Adamson G, Collins K (2003) The self-perception profile for children (SPPC): a multiple-indicator multiple-wave analysis using LISREL. Pers Indiv Differ 35:1993-2005
36. Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116
37. Suskauer SJ, Cintas HL, Marini JC, Gerber LH (2003) Temperament and physical performance in children with osteogenesis imperfecta. Pediatrics 111:E153-E161
38. van Dongen-Melman JEWM, Koot HM, Verhulst FC (2001) Cross-cultural validation of Harter's self-perception profile for children in a Dutch sample. Educ Psychol Meas 739-753
39. Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, Roughley PJ, Glorieux FH (2002) Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 31:12-18
40. Willing MC, Pruchno CJ, Atkinson M, Byers PH (1992) Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen. Am J Hum Genet 51:508-515
41. Zacharin M, Kanumakala S (2004) Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 17:1511-1517